{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:06Z","timestamp":1786992006730,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.02.019","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T18:39:07Z","timestamp":1712515147000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-2076","authenticated-orcid":false,"given":"Tamara","family":"Gracia Caza\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Riera Monroig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Izu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Yanguas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lorda Esp\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"S\u00e1nchez Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Fernando","family":"Garc\u00eda Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Navarro Bielsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Aldea Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Almenara Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Garc\u00eda-Latasa de Aran\u00edbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Fuentelsaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Morales Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Ara-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdin.2024.02.019_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.02.019_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.02.019_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2024.02.019_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028530","article-title":"Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer","volume":"10","author":"Yan","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"10.1016\/j.jdin.2024.02.019_bib5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jdin.2024.02.019_bib6","doi-asserted-by":"crossref","first-page":"AB174","DOI":"10.1016\/j.jaad.2021.06.708","article-title":"28095 Long-term safety of guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2024.02.019_bib7","doi-asserted-by":"crossref","first-page":"AB63","DOI":"10.1016\/j.jaad.2019.06.258","article-title":"Experience in patients with a history of malignancy through 3 years of continuous treatment with guselkumab in the VOYAGE 1 and 2 trials","volume":"81","author":"Blauvelt","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.02.019_bib8","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.4081\/dr.2022.9282","article-title":"Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis","volume":"14","author":"Mastorino","year":"2022","journal-title":"Dermatol Reports"},{"issue":"7101","key":"10.1016\/j.jdin.2024.02.019_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jdin.2024.02.019_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.02.019_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/bjd\/ljad081","article-title":"Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","volume":"189","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2024.02.019_bib12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.02.019_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"10.1016\/j.jdin.2024.02.019_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jdin.2024.02.019_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1684\/ejd.2020.3860","article-title":"Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer","volume":"30","author":"Kamiya","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.02.019_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.06.642","article-title":"27629 Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T22:59:29Z","timestamp":1740869969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":16,"alternative-id":["S2666328724000580"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.02.019","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}